Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
754 ARTICLES BY Jacob Bell
- Nov. 16, 2018 MYSTIC deals another blow to AstraZeneca as Imfinzi misses on OS
- Nov. 15, 2018 3 hemophilia patients lift uniQure's value more than $450M
- Nov. 15, 2018 7 drugs that raised eyebrows in Q3
- Nov. 14, 2018 Pfizer launches biosimilar version of Amgen's Epogen
- Nov. 13, 2018 Sobi snags rights to AstraZeneca drugs in another immunology play
- Nov. 12, 2018 AstraZeneca calls victory in CV study, but will payers feel the same?
- Nov. 9, 2018 Gilead's search for the next great liver drug won't end with its FXR agonist
- Nov. 8, 2018 AmerisourceBergen's compounding site still on ice despite beefed-up oversight
- Nov. 8, 2018 PARP makers search for a way to break through
- Nov. 7, 2018 Earnings reveal pharma's mixed feelings on Trump drug pricing proposal
- Nov. 6, 2018 Despite Trulicity success, Lilly can't escape diabetes concerns
- Nov. 5, 2018 Lilly strengthens Trulicity's leading position with REWIND results
- Oct. 29, 2018 Red pill or blue? It could be a billion-dollar decision
- Oct. 25, 2018 Endocyte deal showcases Novartis' complex manufacturing juggling act
- Oct. 25, 2018 Biogen dips as BAN2401 data bring more questions than answers
- Oct. 24, 2018 Amgen cuts US Repatha price 60% amid market pressure
- Oct. 24, 2018 DTC's big issues: Trump, cancer drugs and the First Amendment
- Oct. 24, 2018 Cryoport, in pursuit of smoother cell therapy logistics, opens new facility
- Oct. 23, 2018 Biogen talks threats to Spinraza, but mum on BAN2401
- Oct. 22, 2018 Lynparza hits a 'home run,' putting pressure on other PARP inhibitors
- Oct. 19, 2018 FDA unconvinced by Novartis pitch for canakinumab
- Oct. 18, 2018 Fresh data expands Pfizer's options for treating first-line kidney cancer
- Oct. 17, 2018 Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices
- Oct. 17, 2018 Amgen, Lilly migraine drugs make it onto Express Scripts' preferred list
- Oct. 16, 2018 J&J sees 'evolution in pricing, not a revolution' in 2019